Patents by Inventor Levi A. Garraway

Levi A. Garraway has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions And Methods Of Treating Head And Neck Cancer
    Publication number: 20130171124
    Abstract: The present invention provides methods related to the treatment of head and neck squamous cell carcinoma (HNSCC) and its associated premalignant lesions. In particular, the invention features methods which may specifically target HNSCC-associated genes and alter gene expression to treat or alleviate a symptom of HNSCC, or its related premalignant lesions. These methods may involve decreasing the function of an HNSCC-associated gene with aberrant gain-of-function; or increasing the function of an HNSCC-associated gene with aberrant loss-of-function.
    Type: Application
    Filed: July 25, 2012
    Publication date: July 4, 2013
    Inventors: Le Cong, Ann Marie Egloff, Levi A. Garraway, Jennifer Rubin Grandis, Eric S. Lander, Nicholas Stransky, Aaron D. Tward, Feng Zhang
  • MEK1 Mutation Conferring Resistance to RAF and MEK Inhibitors
    Publication number: 20130143911
    Abstract: Nucleic acids and proteins having a mutant MEK sequence, and methods concerning identification of patients having resistance to treatment with anti-cancer agents, specifically inhibitors of RAF or MEK are provided. Methods of treatment and for optimizing treatment for patients having a mutation in a MEK1 sequence are also provided.
    Type: Application
    Filed: June 9, 2011
    Publication date: June 6, 2013
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: Levi A. Garraway, Caroline Emery, Nikhil Wagle
  • Methods of Diagnosing and Treating Cancer in Patients Having or Developing Resistance to a First Cancer Therapy
    Publication number: 20130059851
    Abstract: A method of identifying a subject having cancer who is likely to benefit from treatment with a combination therapy with a RAF inhibitor and a second inhibitor is provided. A method of treating cancer in a subject in need thereof is also provided and includes administering to the subject an effective amount of a RAF inhibitor and an effective amount of a second inhibitor, wherein the second inhibitor is a MEK inhibitor, a CRAF inhibitor, a CrkL inhibitor or a TPL2/COT inhibitor. A method of identifying a kinase target that confers resistance to a first inhibitor is also provided.
    Type: Application
    Filed: March 9, 2011
    Publication date: March 7, 2013
    Applicant: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Levi A. Garraway, Cory M. Johannessen
  • BRAF Mutations Conferring Resistance to BRAF Inhibitors
    Publication number: 20130004509
    Abstract: The present invention relates to methods, compositions and kits concerning resistance to treatment with an anti-cancer agent, specifically an inhibitor of BRAF. In particular embodiments, the invention concerns mutations in a BRAF sequence that confer resistance to a BRAF inhibitor. Identification of such mutations in a BRAF sequence allows the identification and design of second-generation BRAF inhibitors. Methods and kits for detecting the presence of a mutant BRAF sequence in a sample are also provided.
    Type: Application
    Filed: February 22, 2011
    Publication date: January 3, 2013
    Inventor: Levi Garraway
  • MEK MUTATIONS CONFERRING RESISTANCE TO MEK INHIBITORS
    Publication number: 20120015973
    Abstract: The present invention relates to methods, compositions and kits concerning resistance to treatment with an anti-cancer agent, specifically an inhibitor of MEK. In particular embodiments, the invention concerns mutations in a MEK sequence that confer resistance to a MEK inhibitor. Identification of such mutations in a MEK sequence allows the identification and design of second-generation MEK inhibitors. Methods and kits for detecting the presence of a mutant MEK sequence in a sample are also provided.
    Type: Application
    Filed: December 10, 2009
    Publication date: January 19, 2012
    Applicants: Novartis AG, Dana-Farber Cancer Institute, Inc.
    Inventors: Levi A. Garraway, Caroline Emery, Carlos Garcia Echeverria
  • Methods for identifying and using SNP panels
    Patent number: 7981609
    Abstract: Described are methods for identifying single nucleotide polymorphism (SNPs) that are useful for analyzing genetic samples, and for using said SNPs to determine genetic identity of samples.
    Type: Grant
    Filed: June 8, 2007
    Date of Patent: July 19, 2011
    Assignees: The Brigham and Women's Hospital, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: Mark A. Rubin, Francesca Demichelis, Levi A. Garraway, William R. Sellers
  • Methods for identifying and using SNP panels
    Publication number: 20090004652
    Abstract: Described are methods for identifying single nucleotide polymorphism (SNPs) that are useful for analyzing genetic samples, and for using said SNPs to determine genetic identity of samples.
    Type: Application
    Filed: June 8, 2007
    Publication date: January 1, 2009
    Inventors: Mark A. Rubin, Francesca Demichelis, Levi A. Garraway, William R. Sellers